ATEC

Business Context and Reporting Period

Company: Alphatec Holdings, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: Alphatec is a medical technology company focused on the design, development, manufacturing, and marketing of products for the surgical treatment of spine disorders, with a specific emphasis on conditions affecting the aging spine. The company operates in the U.S., Asia, and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 35.3% in the three months ended June 30, 2009, compared to the same period in 2008, and 33.6% for the six-month period. Growth was driven by increased sales in the U.S. (Zodiac, Novel, Trestle, Biologics, and Solanas product lines) and Asia, as well as the commencement of sales in Europe.
• Profitability Improvement: The operating loss narrowed significantly from $(19.2) million in the first half of 2008 to $(8.6) million in the first half of 2009. This improvement is largely due to the absence of an $11.0 million litigation settlement expense recorded in the prior year.
• In-Process R&D (IPR&D): IPR&D expenses increased to $4.5 million for the quarter and $5.8 million for the six months ended June 30, 2009, compared to $0 and $1.3 million in the prior year periods. This reflects milestone payments and technology acquisitions (e.g., OsseoScrew, ISI License Agreement).
• Interest Expense: Interest expense increased to $0.9 million for the quarter and $1.8 million for the six months, primarily due to the new Credit Facility entered into in December 2008.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Capital Resources: As of June 30, 2009, the company held $19.7 million in cash and cash equivalents with $0.4 million remaining available under its credit facility. Management believes these resources are sufficient to fund operations through at least June 30, 2010.
• Debt Covenants: The company is subject to financial covenants under its Credit Facility with Silicon Valley Bank and Oxford Finance Corporation, including minimum revenue and Adjusted EBITDA levels. Management believes it will meet these covenants based on its 2009 operating plan, but failure to do so could result in a default and acceleration of debt.
• Recent Financing: In June 2009, the company completed a private placement of 3,937,007 shares of common stock to Healthpoint Capital Partners II, LP, raising approximately $10.0 million (net proceeds ~$9.9 million).
• Legal Proceedings: The company is involved in ongoing litigation with four surgeons (the "Brodke litigation") regarding alleged royalty payments on polyaxial screws. A trial is scheduled for the third quarter of 2009. While management does not believe the outcome will be materially adverse, a significant judgment could trigger a default under the Credit Facility.
• Unusual Items: The prior year's results included a one-time $11.0 million litigation settlement expense. The current period includes significant non-cash IPR&D charges related to technology acquisitions.

Investor Verification Checklist

• Covenant Compliance: Verify the company's ability to meet the escalating quarterly revenue and Adjusted EBITDA covenants required by its Credit Facility to avoid default.
• Litigation Outcome: Monitor the third-quarter 2009 trial regarding the Brodke litigation, as an adverse judgment could impact financial statements and debt status.
• IPR&D Commercialization: Assess the timeline and success of commercializing the newly acquired technologies (e.g., OsseoScrew, ISI device) to ensure future revenue streams justify the current R&D expenses.
• European Expansion: Review the performance of the new European market, noting that revenues are currently deferred due to extended payment terms with distributors.
• Cash Burn Rate: Evaluate the sustainability of the current cash burn rate against the $19.7 million cash balance and the need for potential future financing.